Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

Simon Couillard; Nayia Petousi; Sanjay Ramakrishnan; Renzo Dalla Valle; Amélie Tétu; Samuel Lemaire-Paquette; Changming Xia; Steve Poirier; Olivier Ledanois; Rebecca Gall; Andréanne Côté; Nermin Diab; Philippe Lachapelle; Ian D Pavord

doi:10.1016/j.anai.2026.03.028

April 1, 2026Annals of Allergy Asthma & ImmunologyOpen Access

Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

View Full Paper

Ask AI

Bookmark

Share

Key Points

Assess the effect of dupilumab on inducing clinical remission in at-risk individuals with type-2 inflammatory asthma.
Multinational, investigator-initiated design
Parallel group randomised trial
Double-blind and placebo-controlled setup
Adheres to SPIRIT 2025 guidelines
Results will be reported at international meetings
Findings will be published in peer-reviewed journals

Implication

A phase 3b trial assesses dupilumab's impact on asthma remission in at-risk populations, suggesting potential therapeutic benefits.

Abstract

Approved by the Research Ethics Committee of CIUSSS de l'Estrie-CHUS (MP-31-2026-6116). The protocol follows SPIRIT 2025 guidelines. Results will be disseminated at international meetings and in peer-reviewed journals in accordance with CONSORT.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Couillard et al. (2026) studied this question.

synapsesocial.com/papers/69df2a4be4eeef8a2a6af765 https://doi.org/10.1016/j.anai.2026.03.028

View Full Paper

Ask AI

Bookmark

Share

Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

Key Points

Implication

Abstract

Discussion

Cite This Study

Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading